The prospective use of COX-2 inhibitors for the treatment of temporomandibular joint inflammatory disorders.
Int J Immunopathol Pharmacol
; 16(2 Suppl): 1-9, 2003.
Article
en En
| MEDLINE
| ID: mdl-14552698
ABSTRACT
Development of a new class of drugs designed to selectively inhibit the inducible cyclooxygenase isoenzyme, COX-2, was initially prescribed for individuals diagnosed with osteoarthritis or rheumatoid arthritis. Although these inflammatory disorders are more typically related to the joints of the knee, ankle, or hand, the temporomandibular joint (TMJ) plays a special role due to its involvement in our normal day-to-day activities of eating and communicating. The TMJ, unlike most of the other joints, contains some unique morphological characteristics that support various inflammatory disorders. An overview of these characteristics and the prospective use of the COX-2 inhibitors for temporomandibular joint inflammation are presented.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Articulación Temporomandibular
/
Trastornos de la Articulación Temporomandibular
/
Inhibidores de la Ciclooxigenasa
/
Isoenzimas
Tipo de estudio:
Risk_factors_studies
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Int J Immunopathol Pharmacol
Asunto de la revista:
ALERGIA E IMUNOLOGIA
/
FARMACOLOGIA
/
PATOLOGIA
Año:
2003
Tipo del documento:
Article
País de afiliación:
Estados Unidos